by David Wallace
Hepcidin Mimetic PTG-300 Promising Treatment for PV
How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV? How does iron deficiency play a role in polycythemia vera? What are the goals of this treatment? Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David Wallace, discussing early Phase 2 clinical trial results on PTG-300.
Check out the video to find out more about this new treatment for polycythemia vera. More details on this trial can be found on clinicaltrials.gov.
This program is sponsored by Protagonist Therapeutics, Inc. This organization has no editorial control, it is produced solely by PV Reporter.
